A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Exclusion Criteria

• •Laboratory and medical history parameters not within the Protocol-defined range.
• •Receipt of anticancer medications or investigational drugs within the Protocol-defined intervals before the first administration of study drug.
• •Previous radiotherapy within 2 weeks of starting study therapy.
• •Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• •Has not recovered to ≤ Grade 1 from toxic effects of previous therapy and/or complications from previous surgical intervention before starting study therapy.
• •Receipt of a live vaccine within 30 days of planned start of study therapy.
• •Active infection requiring systemic therapy.
• •Subjects who have any active or inactive autoimmune disease or syndrome.
• •Women who are pregnant or breastfeeding.